人工智能在乳腺超声病变BI-RADS分类中的应用:能否省略过多的随访和活检?
本研究纳入530例患者共715个乳腺肿块,评估商用AI系统与两名乳腺放射科医生对BI-RADS分类的一致性及诊断性能。AI与两名医生的一致性为中等;以AI判为BI-RADS 2类为安全,可潜在避免11%(18/163)的良性病变活检和46.2%(110/238)的随访。AI能有效预测恶性,整合入临床流程有潜力减少不必要的活检和短期随访。
要点
- AI判为BI-RADS 2类的病变无一例恶性,可作为安全分类参考。
- AI判为BI-RADS 3类的病变中有2例最终证实为恶性,需警惕。
- 以AI BI-RADS 2类为安全,可潜在避免11%良性活检和46.2%随访。
核心结论
- AI在预测恶性方面有效,整合入临床流程有潜力减少不必要的活检和短期随访,从而有助于医疗实践的可持续性。
研究设计与样本
- 回顾性研究,纳入530例患者的715个乳腺肿块,来自同一机构的三个乳腺影像中心,由九名乳腺放射科医生参与;超声由一名放射科医生获取每个病变的两个正交切面,图像由对患者临床数据不知情的第二名放射科医生回顾性审阅,商用AI系统评估图像,按二分类BI-RADS分类评估计算一致性及诊断性能。
关键影像表现/征象
- 715个乳腺肿块中,134个(18.75%)为恶性,581个(81.25%)为良性。
- AI判为BI-RADS 2类的病变无一例恶性,而AI判为BI-RADS 3类的病变中有2例随后证实为恶性。
诊断标准与关键数值
- 在区分良性和可能良性病变与可疑病变时,AI与第一和第二放射科医生的一致性经统计学评估为中等。
- 放射科医生1、放射科医生2和AI的敏感度分别为98.51%、97.76%、98.51%,特异度分别为80.72%、75.56%、65.40%。
- 放射科医生1的阳性预测值为54.10%、阴性预测值为99.58%、准确率为84.06%;放射科医生2分别为47.99%、99.32%、79.72%;AI系统分别为39.64%、99.48%、71.61%。
- 以AI判定的BI-RADS 2类为安全,可潜在避免11%(18/163)的良性病变活检和46.2%(110/238)的随访。
临床应用与阅片要点
- AI判为BI-RADS 2类的病变无一例恶性,可作为阅片时判定良性病变的参考。
- AI判为BI-RADS 3类的病变中有2例最终证实为恶性,报告时需留意此类病变的恶性可能。
- 作者认为将AI整合入临床流程有潜力减少不必要的活检和短期随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Artificial intelligence (AI) systems have been increasingly applied to breast ultrasonography. They are expected to decrease the workload of radiologists and to improve diagnostic accuracy. The aim of this study is to evaluate the performance of an AI system for the BI-RADS category assessment in breast masses detected on breast ultrasound. MATERIALS AND METHODS: A total of 715 masses detected in 530 patients were analyzed. Three breast imaging centers of the same institution and nine breast radiologists participated in this study. Ultrasound was performed by one radiologist who obtained two orthogonal views of each detected lesion. These images were retrospectively reviewed by a second radiologist blinded to the patient's clinical data. A commercial AI system evaluated images. The level of agreement between the AI system and the two radiologists and their diagnostic performance were calculated according to dichotomic BI-RADS category assessment.
RESULTS: This study included 715 breast masses. Of these, 134 (18.75%) were malignant, and 581 (81.25%) were benign. In discriminating benign and probably benign from suspicious lesions, the agreement between AI and the first and second radiologists was moderate statistically. The sensitivity and specificity of radiologist 1, radiologist 2, and AI were calculated as 98.51% and 80.72%, 97.76% and 75.56%, and 98.51% and 65.40%, respectively. For radiologist 1, the positive predictive value (PPV) was 54.10%, the negative predictive value (NPV) was 99.58%, and the accuracy was 84.06%. Radiologist 2 achieved a PPV of 47.99%, NPV of 99.32%, and accuracy of 79.72%. The AI system exhibited a PPV of 39.64%, NPV of 99.48%, and accuracy of 71.61%. Notably, none of the lesions categorized as BI-RADS 2 by AI were malignant, while 2 of the lesions classified as BI-RADS 3 by AI were subsequently confirmed as malignant. By considering AI-assigned BI-RADS 2 as safe, we could potentially avoid 11% (18 out of 163) of benign lesion biopsies and 46.2% (110 out of 238) of follow-ups.
CONCLUSION: AI proves effective in predicting malignancy. Integrating it into the clinical workflow has the potential to reduce unnecessary biopsies and short-term follow-ups, which, in turn, can contribute to sustainability in healthcare practices.
引用
- Guldogan N, Taskin F, Icten GE, et al. Artificial Intelligence in BI-RADS Categorization of Breast Lesions on Ultrasound: Can We Omit Excessive Follow-ups and Biopsies? Acad Radiol. 2023. PMID: 38087719. doi:10.1016/j.acra.2023.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。